US EditionWilliam Blair Reaffirms “Market Perform” Rating for Nektar Therapeutics (NASDAQ:NKTR)
Summary by americanbankingnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
William Blair Reaffirms “Market Perform” Rating for Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating restated by analysts at William Blair in a research note issued to investors on Monday,RTT News reports. Other analysts also recently issued research reports about the company. Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
